Skin Reactions to Linezolid: Clinical Spectrum, Risk Factors, and Therapeutic Implications

Linezolid is indispensable for multidrug resistant Gram-positive infections, yet cutaneous adverse events complicate therapy and may threaten patient safety. We synthesized the clinical spectrum, putative risk factors, and management strategies from published reports to inform bedside decision making. We compiled a curated set of PubMed indexed human reports on linezolid associated skin reactions and performed structured screening, duplicate removal, and qualitative synthesis. Outcomes included reaction phenotype, timing, severity, management, and resolution, while study design features and reporting completeness were appraised to contextualize certainty. Seventeen publications from 2015 to 2023 described linezolid associated skin reactions across diverse settings and journals. Titles and article metadata indicated a predominance of case reports and small series, with events spanning exanthematous eruptions, vasculitic presentations, photosensitivity reactions, and severe immune mediated syndromes such as DRESS. Signals for phenotype specific management were consistent with standard drug hypersensitivity care, emphasizing immediate withdrawal, supportive measures, and graded use of systemic corticosteroids or immunomodulatory therapy in severe disease. Where follow up was available, most events improved after cessation, though reporting of time to resolution and rechallenge outcomes was limited. Across studies, inconsistent terminology and heterogeneous outcome definitions constrained meta-analytic pooling and reduced comparability. The literature confirms a clinically meaningful spectrum of linezolid associated cutaneous reactions that ranges from self-limited rashes to life threatening hypersensitivity syndromes. Early recognition, prompt discontinuation, and severity guided escalation of care are central to management. Standardized phenotyping, prospective capture of time to onset and resolution, and careful documentation of concomitant exposures are needed to clarify risk factors, refine counseling, and enable comparative safety analyses across antibiotic classes.